PRODUCT DISCONTINUATION NOTIFICATION COULD BE ADDED TO HOUSE FDA REFORM BILL; REP. BURR IS SAID TO BE CONSIDERING COMPROMISE ON ANTIBIOTIC EXCLUSIVITY
A provision to require manufacturers to provide notice of discontinuance of products used to treat serious or life threatening conditions could be added to the House FDA reform measure (HR 1411) prior to a full committee markup set for Sept. 25, House Commerce/Health Subcommittee Chairman Bilirakis (R-Fla.) indicated at a subcommittee markup of the legislation Sept. 17.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth